Today: 30 June 2026
Browse Category

NASDAQ:LEMSE 7 October 2025

Leading Edge Materials (0V3V.L) Surges Amid EU Critical Minerals Boom – Latest News, Stock Trends & Outlook

Leading Edge Materials (0V3V.L) Surges Amid EU Critical Minerals Boom – Latest News, Stock Trends & Outlook

In the first week of October 2025, Leading Edge Materials drew significant attention after a sudden share price spike. On October 6, the stock jumped 27.7% in a single trading sessionstockinvest.us. This leap continued a short-term rally that saw the stock gain over 40% in two weeksstockinvest.us. Such volatility suggests speculative buying, likely driven by positive sentiment around the company’s recent news and the broader critical minerals narrative. Investors may be anticipating upcoming catalysts, notably the decision on the Norra Kärr mining lease expected by the end of 2025leadingedgematerials.com, as well as Europe’s intensified efforts to shore up its battery metal supply chains. Just prior to this rally, Leading Edge announced a key regulatory update: on September 22, 2025, it confirmed that its Swedish subsidiary had submitted all supplementary information requested by authorities for the Norra Kärr Heavy Rare Earth Elements Project mining concession applicationleadingedgematerials.com. This step was in response to detailed questions from county regulators about environmental impacts, and the completed application is now under review by Sweden’s Mining Inspectorateleadingedgematerials.com. The Norra Kärr deposit is strategically important – the Geological Survey of Sweden has noted it is “very important for Sweden’s and the EU’s supply of rare earth metals”

Stock Market Today

  • Zenas BioPharma (Zenas) Lawsuit Over IPO Cash Burn Dismissed
    June 30, 2026, 2:15 PM EDT. Zenas BioPharma Inc. beat a lawsuit claiming it misled investors about its cash burn rate before its IPO. U.S. District Judge Leo T. Sorokin tossed the proposed class action, saying the investor did not show an actionable omission. The judge ruled Zenas did not have to provide more detailed spending or interim 2024 Q3 data before going public. The decision takes legal pressure off Zenas BioPharma for now on these disclosure issues.
Go toTop